Denali, ALS and Therapeutics

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.
Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...
New research on the Denali Fault reveals three geologic sites were once united in a suture zone, marking the integration of ...
Then-US President Barack Obama officially returned North America's tallest mountain to its Indigenous name in 2015 - Anadolu ...
Denali Bancorporation, Inc., the parent company of Denali State Bank, announced a $0.05 increase in its quarterly cash ...
Mashpee Wampanoag educator Kitty Hendricks-Miller (Nanaweetah), consults on PBS 'Molly of Denali' as Cape-based tribe debuts ...
Fintel reports that on January 3, 2025, William Blair initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a ...